One poster presentation will include updated clinical safety and
efficacy data from the Phase 1b basket study of RXDX-105, the company’s
VEGFR-sparing, potent RET
inhibitor.

The company’s data that examine a novel combination of entrectinib — the
company’s orally available, CNS-penetrant tyrosine kinase inhibitor
targeting tumors that harbor TRK,
ROS1 or ALK fusions — with trametinib, designed to overcome drug
resistance to TRK inhibition, will be presented as a late-breaking oral
plenary presentation.

The company also announced four additional poster presentations related
to its robust pipeline of molecularly targeted oncology therapies —
entrectinib, RXDX-105, and RXDX-106. These will be the first data Ignyta
has disclosed for RXDX-106, and the data presented in the posters
highlight both immuno-therapeutic and targeted activity of this novel
agent.

“We are excited to provide updated clinical and preclinical data across
multiple compounds from our cancer precision medicine pipeline,” said
Pratik Multani, M.D., Ignyta’s Chief Medical Officer. “In particular,
the team is excited to present new clinical data on RXDX-105, and is
honored that the ENA Scientific Program Committee has chosen entrectinib
for an oral plenary presentation.”

Details of the presentations are as follows:

Late-Breaking Oral Plenary Presentation:

Title:

Overcoming drug resistance to Trk inhibition by rational
combination of entrectinib and trametinib: from bench to bedside
(Abstract number 8LBA)

A copy of the presentation and posters will be made available during the
sessions in the Scientific Presentations section of the company's
website at http://www.ignyta.com,
and will be archived and available at that site.

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

At Ignyta, we work tirelessly on behalf of patients with cancer to offer
potentially life-saving, precisely targeted therapeutics (Rx) guided by
companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us
to enter uncharted territory, illuminating the molecular drivers of
cancer and quickly advancing treatments to address them. This approach
embraces even those patients with the rarest cancers, who have the
highest unmet need and who may otherwise not have access to effective
treatment options. With our pipeline of potentially first-in-class and
best-in-class precision medicines, we are pursuing the ultimate goal of
not just shrinking tumors, but eradicating cancer relapse and recurrence
in precisely defined patient populations.

This press release contains forward-looking statements about Ignyta as
that term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Statements in this
press release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other things,
references to the results of the Phase 1 clinical study of RXDX-105 and
the development of Ignyta's product candidates. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company; Ignyta's ability to
develop, initiate or complete preclinical studies and clinical trials
for, obtain approvals for and commercialize any of its product
candidates; changes in Ignyta's plans to develop and commercialize its
product candidates; the potential for final results of the ongoing
clinical trials of RXDX-105 or other product candidates, or any future
clinical trials of RXDX-105 or other product candidates, to differ from
preliminary or expected results; Ignyta's ability to raise any
additional funding it will need to continue to pursue its business and
product development plans; regulatory developments in the United
States and foreign countries; Ignyta's ability to obtain and maintain
intellectual property protection for its product candidates; the risk
that orphan drug exclusivity may not effectively protect a product from
competition and that such exclusivity may not be maintained; the
potential for the company to fail to maintain the CAP accreditation and
CLIA certification of its diagnostic laboratory; the loss of key
scientific or management personnel; competition in the industry in
which Ignyta operates; and market conditions. These forward-looking
statements are made as of the date of this press release,
and Ignyta assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ
from those projected in the forward-looking statements. Investors should
consult all of the information set forth herein and should also refer to
the risk factor disclosure set forth in the reports and other documents
the company files with the SEC available at www.sec.gov,
including without limitation Ignyta's Annual Report on Form 10-K for the
year ended December 31, 2015 and subsequent Quarterly Reports on Form
10-Q.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.